HealthEcon Ltd, Basel, Switzerland, 2 Vifor Ltd. Pharmaceutical Specialties, Villars-sur-Glâne, Switzerland OBJECTIVES: IDA, the most common form of anaemia, has a relatively high prevalence across Europe. IDA is common in pregnancy, postpartum and inflammatory bowel disease (IBD) with IDA prevalences of 18, 17 and 33% respectively. At present, treatment with parenteral iron substitution is limited by the amount of iron which can be administered intravenously in any one application. This study estimates the BI associated with partially substituting the standard i.v. treatment, iron sucrose, with a new treatment, ferric carboxymaltose, allowing for the application of higher dosages in a shorter time. The study adopted the perspective of the Swiss mandatory health insurance over 3 years covering the indications pregnancy, postpartum and IBD. METHODS: Resource use was based on primary data and guidelines. Costs were estimated using a feefor-service reimbursement system (Tarmed), including drug, personnel and other costs. The price of ferric carboxymaltose was assumed to be that of iron sucrose +40%. The BI was estimated for the first 3 years post-launch, using a substitution rate of 20% in year 1 and 50% in year 2 and 3. RESULTS: Ferric carboxymaltose reduces the costs per treatment cycle and patient in IBD by 35% compared to iron sucrose (CHF 475 vs. CHF 732), due to reduced personnel costs: 1000 mg iron requires one application with ferric carboxymaltose and 5 for iron sucrose (200 mg each). Total savings to the Swiss mandatory health insurance amount to approx. CHF 1 Mio (approx. € 611′600) in year 1 and approx. CHF 2.5 Mio in year 2 and 3 each. Costs were also reduced by 33% in the gynaecological indication using smaller, empirical dosages of 500 mg. CON-CLUSION: Treating IDA involves substantial costs to the Swiss mandatory health insurance. Substitution of iron sucrose by ferric carboxymaltose may help to reduce these due to saved personnel costs, despite higher product costs. To analyze cost-effectiveness of bortezomib versus dexamethasone for recurrent or treatment-resistant multiple myeloma in Russian health care system. METHODS: The study was performed from the Russian reimbursement system point of view. An economic model prepared for the submission to National Institute of Health and Clinical Excellence was used as a framework. Effect of studied drugs was measured in life-years gained. The effectiveness was estimated on the basis of APEX study results and complemented with prognosis of long-term outcomes. Direct medical costs for medication were included into the model, registered prices were taken from the Russian reimbursement list while dose regimen and number of treatment courses were considered to be equal to those used in APEX study. The incremental cost-effectiveness ratio (CER) was calculated.
PHM3 CLINICO-ECONOMICAL ANALYSIS OF BORTEZOMIB VS

RESULTS:
The incremental effectiveness of bortezomib versus dexamethasone was estimated as 2,371-2,739 life-years gained (the interval includes minimal and maximal values identified by different approaches to long-term outcomes projection). The incremental cost was 1 822 774,00 rubles (about 70 thousands USD). The incremental CER was 67,510,148 -792,510,43 rubles (25-29 thousands USD) per life-year gained. CONCLU-SION: The incremental CER for bortezomib is comparable with other expensive drugs included into the reimbursement system. Further studies are needed to assess cost-effectiveness of bortezomib vs other therapeutic strategies used for resistant and recurrent multiple myeloma and to evaluate effectiveness in medical practice. as an on-demand/prophylactic modality for hemophilia A (HA) treatment compared to the best current Finnish treatment practice (Kogenate) in a scenario where a pathogen emerges and is transmitted trough non-PFM methods as the Hepatitis C virus (HCV) in the 1980's. METHODS: Incremental costeffectiveness analysis was performed using probabilistic simulation to depict uncertainty. Conservative information related to treatment practices, costs and survival in Finland were gathered from literature and clinical experts. HIV and HBV were excluded from the modeling, because only 2 HIVs have been transmitted through coagulant products to Finnish HA patients and efficient vaccinations against HBV infection exists. Our innovation, PII, is discussed elsewhere. Here, PII was used to assess the interval when the extra treatment costs of ADVATE are compensated by the treatment costs of emerging pathogen (i.e. interval when no pathogens should emerge, if non-PFM method is used). RESULTS: Current treatment practice was dominated by the ADVATE scenario. 18 years old HA male with and without pathogen transmission had survival estimates of 48 and 55 years, respectively. The expected difference in survival was 3.48 years (51% less pathogen transmissions). Mean treatment cost differences were 7,500-50,200 €/year and 213,700-2,381,600 €/lifetime favoring ADVATE. All PIIs for annual ADVATE investment favored ADVATE and were 1-7 years depending on patient's weight, age, and treatment modality. When production losses and discounting of costs and effectiveness (5%) were included in sensitivity analysis, the relative differences increased (e.g. PIIs became 1-9 years due to production losses). CONCLUSION: ADVATE improves survival, is cost-effective and offers good long-term investment in the treatment of hemophilia A, when known/unknown pathogens transmitted through non-PFM methods emerge. When investment's safety is of concern, PII offers new hands-on interpretation for the political discussion. Intravenous iron is a cost-effective alternative to oral iron, in treatment of iron deficiency anemia in oncology, CKD and postpartum patients.
PHM4 CLINICO-ECONOMICAL ANALYSIS OF FERRUM LEK VS FENULS IN IRON-DEFICIENT ANEMIA IN ELDERLY PATIENTS
PHM6 COST-EFFECTIVENESS OF INTRAVENOUS IRON VERSUS ORAL IRON IN ANEMIA TREATMENT IN ONCOLOGY, CHRONIC KIDNEY DISEASE AND POST-PARTUM PATIENTS
PHM7 COST SIMULATION OF NOVOSEVEN VERSUS FEIBA AND ITT-F8 FOR PRIMARY PROPHYLAXIS TREATMENT OF HAEMOPHILIA A/B PATIENTS WITH INHIBITORS
Weatherall JH Novo Nordisk, Bagsvaerd, Denmark OBJECTIVES: Haemophilia patients with inhibitors characteristically have high annual drug costs and other health care related costs. There are essentially three treatment options: NovoSeven, FEIBA or ITT followed by regular F8 treatment. Aim: This cost-minimization simulation examines the treatment costs of NovoSeven versus FEIBA and ITT/F8 for haemophilia A/B patients with inhibitors. METHODS: The simulation is based on a standard set of assumptions for an average severe haemophilia patient. First, primary prophylaxis treatment is defined by daily treatment on an annual basis of 50 ìG/KG for NovoSeven and 40 IU/KG for FEIBA. ITT-F8 treatment follows the Bonn Protocol for ITT at 300 IU/KG followed by F8 at 15 IU/KG. Second, we assume 2 breakthrough bleeds per month. Third, the patients weight changes each year throughout a 21 year child-adolescent-manhood life cycle time series model according to average yearly weight changes for boys in the standard population. Fourth, costs are based on estimated average global realised wholesaler purchaser prices in EUROS. ITT-F8 costs 0.7271 EUROS for an IU/KG. FEIBA costs 1.143216 EUROS for an IU/KG. NovoSeven costs 0.9191 EUROS for an ìG/KG. Costs are also discounted at a rate of 3.5 percent a year over time. RESULTS: Annual N7 costs for a 70 KG patient are 990.662 EUROS per year. Annual FEIBA costs for a 70 KG patient are 1.168.367 EUROS per year. Annual ITT treatment is 11.146.504 EUROS and annual F8 treatment costs are 277.679 EUROS. CONCLUSION: Novo Seven is slightly cheaper compared to FEIBA for certain dosing regimens. NovoSeven is also cheaper than ITT-F8 for the first 6-7 years after treatment begins.
